Cravath’s New York Office Moves to Two Manhattan West
Cravath represents some of the largest and most highly regarded companies in the healthcare and life sciences industries, providing counsel on a variety of corporate and litigation matters across the entire global innovation marketplace. We have played a leading role in critical and complex matters that have defined these industries, creating long‑standing client relationships and enhancing our ability to handle the unique matters in these sectors.
Our corporate lawyers have steered some of the largest and most significant U.S. and non‑U.S. transactions in the healthcare and life sciences industries. We have advised a full spectrum of companies, from biotechnology startups to established healthcare and life sciences companies, in connection with transactions ranging from complex collaboration agreements to a wide variety of acquisitions and divestitures of companies and businesses. Clients also rely on our financing expertise as well as our experience in navigating risks and strategies related to environmental, social and governance (“ESG”) issues.
Our litigators have an extensive understanding of substantive issues coupled with deep trial experience and have litigated numerous matters in the healthcare and life sciences areas. We have handled matters for pharmaceutical, healthcare services and medical device companies, including antitrust litigation and regulatory clearance, class actions, shareholder derivative and securities suits, breach of contract and licensing disputes and arbitrations. Our experience also extends to the field of biotechnology, with particular expertise navigating the biologics and biosimilars landscape.
Intellectual property issues are critical for many of our clients in these sectors. We have significant expertise across a broad range of intellectual property issues including strategic counseling, complex intellectual property litigation, review and analysis in developing and optimizing intellectual property rights, patents, licensing and portfolio development and exploitation.
Our corporate lawyers have steered some of the largest and most significant U.S. and non‑U.S. transactions in the healthcare and life sciences industries. We have advised a full spectrum of companies, from biotechnology startups to established healthcare and life sciences companies, in connection with transactions ranging from complex collaboration agreements to a wide variety of acquisitions and divestitures of companies and businesses. Clients also rely on our financing expertise as well as our experience in navigating risks and strategies related to environmental, social and governance (“ESG”) issues.
Our litigators have an extensive understanding of substantive issues coupled with deep trial experience and have litigated numerous matters in the healthcare and life sciences areas. We have handled matters for pharmaceutical, healthcare services and medical device companies, including antitrust litigation and regulatory clearance, class actions, shareholder derivative and securities suits, breach of contract and licensing disputes and arbitrations. Our experience also extends to the field of biotechnology, with particular expertise navigating the biologics and biosimilars landscape.
Intellectual property issues are critical for many of our clients in these sectors. We have significant expertise across a broad range of intellectual property issues including strategic counseling, complex intellectual property litigation, review and analysis in developing and optimizing intellectual property rights, patents, licensing and portfolio development and exploitation.
Deals & Cases
June 24, 2024
On June 24, 2024, Illumina, Inc. (“Illumina”), a global leader in DNA sequencing and array-based technologies, announced the successful completion of the spin-off of GRAIL, a healthcare company whose mission is to detect cancer early. This follows Illumina’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. The separation was achieved through the distribution of 85.5% of the outstanding shares of GRAIL to holders of Illumina common stock on June 24, 2024. In addition to retaining their shares of Illumina common stock, Illumina shareholders received one share of GRAIL common stock for every six shares of Illumina stock held as of close of business on the record date of June 13, 2024. Illumina retained 14.5% of the outstanding shares of GRAIL common stock. Cravath represented Illumina in connection with the transaction.
Deals & Cases
June 17, 2024
Cravath represented the initial purchasers in connection with the $1.225 billion 144A/Reg. S high‑yield senior secured notes offering of CHS/Community Health Systems, Inc. CHS/Community Health Systems, Inc., together with its parent company, Community Health Systems, Inc., is one of the nation’s largest healthcare companies. The transaction closed on June 5, 2024.
Deals & Cases
May 14, 2024
Cravath represented the placement agent in connection with the €1 billion private placement of senior secured notes of Grifols, S.A., a global healthcare company leading in essential plasma‑derived medicines and transfusion medicine. The transaction closed on April 30, 2024.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
April 29, 2024
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Accolades
July 19, 2024
On July 17, 2024, the India Business Law Journal named Cravath among the “Key Players” in its 2024 ranking of the leading foreign law firms involved in India‑related work. The publication noted that Cravath “is often appointed on complex, high‑value deals involving Indian parties” and highlighted its representation of Tata Technologies Limited in its IPO, as well as Viatris in the divestitures of its Women’s Healthcare business and Active Pharmaceutical Ingredient business in India. Interviewees said the Firm is “proactive in covering matters and anticipating the next steps” and has “offered excellent services,” highlighting the work of Cravath partner Philip J. Boeckman.
Accolades
July 17, 2024
On June 6, 2024, Cravath partner David R. Marriott was recognized by Leaders League as a leading trial lawyer in the United States. The profile praised Dave’s “uncommon ability to consistently win complex cases of every hue, often against all odds,” as exemplified by his representation of clients including Illumina in its unprecedented antitrust trial victory against the FTC; Amgen in its successful defense against the FTC’s challenge to its $27.8 billion acquisition of Horizon Therapeutics; Louis Dreyfus Company and Imperial Sugar Company in their trial victory over the DOJ; Viatris in its summary judgment win to defeat a securities class action; and photographers Donald Graham and Eric McNatt, who secured favorable SDNY judgments in copyright infringement litigation against appropriation artist Richard Prince and his galleries. The publication deemed his work on the antitrust cases “a string of stunning…victories” in “three of the most significant antitrust cases of the last decade.” Leaders League further remarked that “Marriott never shirks from a challenge, no matter how daunting [the] odds or opposition.”
Accolades
June 13, 2024
The IAM Patent 1000 2024, which recognizes the firms and individuals “deemed outstanding in the pivotal area of patent law,” ranked Cravath in the top tier for New York across Litigation and Transactions. In addition, Cravath partners Keith R. Hummel, David J. Kappos, David R. Marriott, Sasha Rosenthal‑Larrea and Sharonmoyee Goswami were recognized for their “outstanding service” and representation of clients on litigation and transactional matters including Johnson & Johnson in its $16.6 billion acquisition of Abiomed; Abiomed in its victory before the U.S. Patent Trial and Appeal Board; and Truist Bank in patent infringement litigation brought by United Services Automobile Association.
Activities & Publications
June 07, 2024
On June 5, 2024, Cravath partner Noah Joshua Phillips participated in the American Bar Association’s 2024 Antitrust in Healthcare Conference, which was held from June 4‑5, 2024, in Arlington, VA. The event convened leading government attorneys, private counsel representing both plaintiffs and defendants, international enforcers and economists to discuss key antitrust issues affecting the healthcare industry and to provide practical advice, insights and policy recommendations. Noah delivered the keynote address entitled “Checkup: Taking the Biden Administration’s Temperature on Healthcare Antitrust.”
Activities & Publications
May 16, 2024
On May 14, 2024, Cravath partner Nicholas A. Dorsey participated in the International Bar Association’s 8th annual Global Entrepreneurship Conference, which was held from May 13‑14, 2024, in Madrid, Spain. Nick co‑chaired a workshop entitled “Selected Financing and Other Topics Relevant for Closely Held Companies,” which examined artificial intelligence and big data; blockchain technology and digital assets; foreign direct investment controls; current sectors, including digital health, energy/renewables and fintech; and trends in private equity and venture capital.
Deals & Cases
June 24, 2024
On June 24, 2024, Illumina, Inc. (“Illumina”), a global leader in DNA sequencing and array-based technologies, announced the successful completion of the spin-off of GRAIL, a healthcare company whose mission is to detect cancer early. This follows Illumina’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. The separation was achieved through the distribution of 85.5% of the outstanding shares of GRAIL to holders of Illumina common stock on June 24, 2024. In addition to retaining their shares of Illumina common stock, Illumina shareholders received one share of GRAIL common stock for every six shares of Illumina stock held as of close of business on the record date of June 13, 2024. Illumina retained 14.5% of the outstanding shares of GRAIL common stock. Cravath represented Illumina in connection with the transaction.
Deals & Cases
June 17, 2024
Cravath represented the initial purchasers in connection with the $1.225 billion 144A/Reg. S high‑yield senior secured notes offering of CHS/Community Health Systems, Inc. CHS/Community Health Systems, Inc., together with its parent company, Community Health Systems, Inc., is one of the nation’s largest healthcare companies. The transaction closed on June 5, 2024.
Deals & Cases
May 14, 2024
Cravath represented the placement agent in connection with the €1 billion private placement of senior secured notes of Grifols, S.A., a global healthcare company leading in essential plasma‑derived medicines and transfusion medicine. The transaction closed on April 30, 2024.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
April 29, 2024
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Accolades
July 19, 2024
On July 17, 2024, the India Business Law Journal named Cravath among the “Key Players” in its 2024 ranking of the leading foreign law firms involved in India‑related work. The publication noted that Cravath “is often appointed on complex, high‑value deals involving Indian parties” and highlighted its representation of Tata Technologies Limited in its IPO, as well as Viatris in the divestitures of its Women’s Healthcare business and Active Pharmaceutical Ingredient business in India. Interviewees said the Firm is “proactive in covering matters and anticipating the next steps” and has “offered excellent services,” highlighting the work of Cravath partner Philip J. Boeckman.
Accolades
July 17, 2024
On June 6, 2024, Cravath partner David R. Marriott was recognized by Leaders League as a leading trial lawyer in the United States. The profile praised Dave’s “uncommon ability to consistently win complex cases of every hue, often against all odds,” as exemplified by his representation of clients including Illumina in its unprecedented antitrust trial victory against the FTC; Amgen in its successful defense against the FTC’s challenge to its $27.8 billion acquisition of Horizon Therapeutics; Louis Dreyfus Company and Imperial Sugar Company in their trial victory over the DOJ; Viatris in its summary judgment win to defeat a securities class action; and photographers Donald Graham and Eric McNatt, who secured favorable SDNY judgments in copyright infringement litigation against appropriation artist Richard Prince and his galleries. The publication deemed his work on the antitrust cases “a string of stunning…victories” in “three of the most significant antitrust cases of the last decade.” Leaders League further remarked that “Marriott never shirks from a challenge, no matter how daunting [the] odds or opposition.”
Accolades
June 13, 2024
The IAM Patent 1000 2024, which recognizes the firms and individuals “deemed outstanding in the pivotal area of patent law,” ranked Cravath in the top tier for New York across Litigation and Transactions. In addition, Cravath partners Keith R. Hummel, David J. Kappos, David R. Marriott, Sasha Rosenthal‑Larrea and Sharonmoyee Goswami were recognized for their “outstanding service” and representation of clients on litigation and transactional matters including Johnson & Johnson in its $16.6 billion acquisition of Abiomed; Abiomed in its victory before the U.S. Patent Trial and Appeal Board; and Truist Bank in patent infringement litigation brought by United Services Automobile Association.
Activities & Publications
June 07, 2024
On June 5, 2024, Cravath partner Noah Joshua Phillips participated in the American Bar Association’s 2024 Antitrust in Healthcare Conference, which was held from June 4‑5, 2024, in Arlington, VA. The event convened leading government attorneys, private counsel representing both plaintiffs and defendants, international enforcers and economists to discuss key antitrust issues affecting the healthcare industry and to provide practical advice, insights and policy recommendations. Noah delivered the keynote address entitled “Checkup: Taking the Biden Administration’s Temperature on Healthcare Antitrust.”
Activities & Publications
May 16, 2024
On May 14, 2024, Cravath partner Nicholas A. Dorsey participated in the International Bar Association’s 8th annual Global Entrepreneurship Conference, which was held from May 13‑14, 2024, in Madrid, Spain. Nick co‑chaired a workshop entitled “Selected Financing and Other Topics Relevant for Closely Held Companies,” which examined artificial intelligence and big data; blockchain technology and digital assets; foreign direct investment controls; current sectors, including digital health, energy/renewables and fintech; and trends in private equity and venture capital.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.